Effects of ceftibuten: A Synthesis of Findings from 26 Studies

  1. Home
  2. Effects of ceftibuten
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of ceftibuten: A Synthesis of Findings from 26 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of ceftibuten: A Synthesis of Findings from 26 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Ceftibuten is an oral third-generation cephalosporin that has shown potent antimicrobial activity against various bacteria, including Enterobacteriaceae. 1 However, its effectiveness can vary depending on the type of bacteria and the site of infection. 1 For example, ceftibuten has shown comparable efficacy to cefaclor in treating bronchitis. 1 It has also been shown to be effective against urinary tract infections caused by E. coli. 26

In vitro studies have indicated that ceftibuten does not significantly interfere with the function of human immune cells. 7 However, some research has shown that ceftibuten may have limited efficacy against certain bacteria, such as beta-lactamase-producing strains. 23 Furthermore, the emergence of resistance to ceftibuten has been reported in specific bacterial strains, particularly group B Streptococcus. 20

Ceftibuten has been observed to undergo isomerization in human serum, transforming into a less active isomer called trans-ceftibuten. 9 This isomerization can potentially reduce the drug's efficacy. 9 Additionally, the absorption of ceftibuten from the human gut can be influenced by various factors, including the presence of other substances and food intake. 6 2

Benefits and Risks

Benefit Summary

Ceftibuten has demonstrated potential in combating various bacteria, particularly E. coli, and is effective in treating bronchitis. 1 26 Moreover, it does not interfere with the function of human immune cells. 7

Risk Summary

Ceftibuten may exhibit limited effectiveness against certain bacterial strains, such as beta-lactamase-producing bacteria. 23 Resistance to ceftibuten has also been documented in specific strains, including group B Streptococcus. 20 Ceftibuten undergoes isomerization in human serum, potentially lowering its efficacy. 9 Furthermore, its absorption from the gut can be affected by other substances and food intake. 6 2

Comparison Across Studies

Commonalities Among Studies

Multiple studies have indicated that ceftibuten exhibits effectiveness against gram-negative bacteria, particularly E. coli. 21 26 Furthermore, it has been shown not to hinder the function of human immune cells. 7

Differences Among Studies

The efficacy of ceftibuten can vary based on bacterial strain and infection site. 1 For example, ceftibuten has shown similar efficacy to cefaclor in treating bronchitis, but it may have limited effectiveness against certain bacteria, such as beta-lactamase-producing strains. 1 23

Consistency and Contradictions in Findings

While multiple studies have demonstrated the effectiveness of ceftibuten against gram-negative bacteria, particularly E. coli, there is a need for further research to determine its efficacy against specific strains and in different infection sites. 21 26 Furthermore, some research has indicated that resistance to ceftibuten can develop in specific bacterial strains, such as group B Streptococcus. 20

Cautions Regarding Real-World Applications

The effectiveness of ceftibuten can vary based on bacterial strain and infection site, so consulting with a physician is crucial before considering its use. 1 Moreover, resistance to ceftibuten can emerge in certain bacterial strains, making close monitoring essential during long-term use. 20 Finally, food intake can affect the absorption of ceftibuten from the gut, emphasizing the importance of following a physician's instructions regarding its use in relation to meals. 2

Limitations of Current Research

Some research on ceftibuten has limitations, such as small sample sizes and a focus on specific bacterial strains, highlighting the need for further research. 1 23

Directions for Future Research

Further research is essential to thoroughly understand the efficacy and safety of ceftibuten. 21 Specific areas of focus include investigating the emergence of resistant strains, exploring factors that influence ceftibuten's effectiveness, and conducting broader studies involving diverse bacterial strains and infection sites. 20

Conclusion

Ceftibuten is a potential antimicrobial agent, particularly against gram-negative bacteria like E. coli, but its effectiveness can be limited against certain bacterial strains and resistance can emerge. Consultation with a physician is crucial when considering the use of ceftibuten. 1 23 20

Literature analysis of 26 papers
Positive Content
22
Neutral Content
0
Negative Content
4
Article Type
2
0
0
0
26
1.

Ceftibuten versus cefaclor for the treatment of bronchitis.

Author: ChirurgiV A, EdelsteinH, OsterS E, KarpR, CassanoK B, AikenS, KrumpeP, McCabeR E

Once-daily dosing
Safe and effective
Treats bronchitis
Few side effects

Ceftibuten, a third-generation cephalosporin, was as effective and safe as cefaclor in treating bronchitis. In a small study of 58 patients, 87.5% of those treated with ceftibuten and 92.3% of those treated with cefaclor showed clinical improvement or cure. Adverse effects were reported in 7.9% of the ceftibuten group and 5.6% of the cefaclor group.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Language : English

2.

Altered diurnal rhythm of intestinal peptide transporter by fasting and its effects on the pharmacokinetics of ceftibuten.

Author: PanXiaoyue, TeradaTomohiro, OkudaMasahiro, InuiKen-ichi

This study found that fasting disrupts the diurnal rhythm of intestinal PEPT1, a transporter protein involved in the absorption of peptide-like drugs. The results suggest that the pharmacokinetics of such drugs may be affected by food intake.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Effects of fatty acid glycerol esters on intestinal absorptive and secretory transport of ceftibuten.

Author: KogaK, MurakamiM, KawashimaS

Enhances intestinal transport

Fatty acid glycerol esters can enhance the intestinal transport of ceftibuten, a cephalosporin antibiotic, by acting on peptide transporters.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

The in vitro effects of ceftibuten on the host defense mechanism.

Author: BragaP C, PiattiG, Dal SassoM, MaciS, BlasiF

No PMN Interference

Ceftibuten is an antibiotic that did not significantly interfere with the function of human polymorphonuclear leukocytes (PMN) at concentrations up to 40 times the minimum inhibitory concentration (MIC) for Escherichia coli.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Effects of protein binding on the isomerization of ceftibuten.

Author: ShimadaJ, HoriS, OgumaT, YoshikawaT, YamamotoS, NishikawaT, YamadaH

Isomerization

Ceftibuten isomerizes to a less active form, trans-ceftibuten, in human serum. This process is accelerated by albumin and contributes significantly to the overall isomerization after oral administration.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

12.

The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinical trial in Sweden.

Author: EdlundCharlotta, TernhagAnders, Skoog StåhlgrenGunilla, EdquistPetra, Östholm BalkhedÅse, AthlinSimon, MånssonEmeli, TempéMaria, BergströmJakob, GiskeChristian G, HanbergerHåkan,

Improved UTI treatment
Reduced antimicrobial resistance

Temocillin, an alternative antibiotic to cefotaxime, may be less prone to disturbing the intestinal microbiota and selecting for antimicrobial resistance. This suggests that temocillin could be a preferred choice for treating febrile UTIs.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes.

Author: TroutRobert E, ZulliAllison, MesarosEugen, JacksonRandy W, BoydSteven, LiuBin, HamrickJodie, DaigleDenis, ChatwinCassandra L, JohnKaitlyn, McLaughlinLisa, CusickSusan M, WeissWilliam J, PulseMark E, PevearDaniel C, MoeckGreg, XerriLuigi, BurnsChristopher J

Oral treatment option
Restored antibiotic activity

This study describes the development of a novel oral prodrug, 36 (VNRX-7145/VNRX-5236 etzadroxil), that inhibits β-lactamases and restores the activity of the oral cephalosporin antibiotic ceftibuten against multi-drug-resistant bacteria. This compound holds promise for treating infections caused by β-lactamase-producing bacteria in an outpatient setting.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Language : English

14.

Discovery of 2-Sulfinyl-Diazabicyclooctane Derivatives, Potential Oral β-Lactamase Inhibitors for Infections Caused by Serine β-Lactamase-Producing Enterobacterales.

Author: FujiuMotohiro, YokooKatsuki, SatoJun, ShibuyaSatoru, KomanoKazuo, KusanoHiroki, SatoSoichiro, AokiToshiaki, KohiraNaoki, KanazawaSachi, WatariRyosuke, KawachiTomoyuki, HirakawaYuya, NagamatsuDaiki, KashiwagiEmi, MakiHideki, YamawakiKenji

Antibacterial Activity
Carbapenem-resistant Enterobacteriaceae
Oral Absorption
Oral BLI

This study discovered a novel diazabicyclooctane (DBO) β-lactamase inhibitor (BLI) that restores the antibacterial activity of ceftibuten against various serine β-lactamase-producing strains, including carbapenem-resistant Enterobacteriaceae (CRE). This BLI can be orally absorbed and exhibits in vivo efficacy in combination with ceftibuten.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

17.

<i>In Vitro</i> Pharmacodynamics of a Novel Ceftibuten-Clavulanate Combination Antibiotic against Enterobacteriaceae.

Author: GrupperMordechai, StaintonSean M, NicolauDavid P, KutiJoseph L

Optimized pharmacodynamics

This study identified the pharmacodynamic index and magnitude for clavulanate (CLA) when combined with ceftibuten (CTB) against ESBL-producing Escherichia coli and Klebsiella pneumoniae. The findings provide insights into exposure requirements for optimizing pharmacodynamics against Enterobacteriaceae.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

18.

Evolution of TEM-type extended-spectrum β-lactamases in Escherichia coli by cephalosporins.

Author: ClasenJulie, BirkegårdAnna Camilla, GræsbøllKaare, FolkessonAnders

ESBL evolution

This study explored the molecular mechanisms behind the development of extended-spectrum β-lactamases (ESBLs), a type of antibiotic resistance enzyme, in response to exposure to different cephalosporin antibiotics. The study also investigated methods for detecting ESBLs in environmental samples.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

19.

Isolation of group B Streptococcus with reduced β-lactam susceptibility from pregnant women.

Author: MoroiHiroaki, KimuraKouji, KotaniTomomi, TsudaHiroyuki, BannoHirotsugu, JinWanchun, WachinoJun-Ichi, YamadaKeiko, MitsuiTakashi, YamashitaMamoru, KikkawaFumitaka, ArakawaYoshichika

GBS infection prevention
GBS infection treatment
Reduced beta-lactam susceptibility

GBS-RBS isolates, harboring amino acid substitutions in PBP2X, were found in pregnant women for the first time, highlighting the emergence of antibiotic resistance and the need for continued surveillance.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Language : English

21.

Identification and Ranking of Clinical Compounds with Activity Against Log-phase Growing Uropathogenic Escherichia coli.

Author: NiuHongxia, YeeRebecca, CuiPeng, ZhangShuo, TianLili, ShiWanliang, SullivanDavid, ZhuBingdong, ZhangWenhong, ZhangYing

New drug candidates for UTIs

Clinafloxacin and pazufloxacin were newly identified antibiotics effective against uropathogenic Escherichia coli (UPEC).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

26.

Comparative in vitro activity of oral antimicrobial agents against Enterobacteriaceae from patients with community-acquired urinary tract infections in three European countries.

Author: KreskenM, Körber-IrrgangB, BiedenbachD J, BatistaN, BesardV, CantónR, García-CastilloM, Kalka-MollW, PascualA, SchwarzR, Van MeenselB, WisplinghoffH, SeifertH

Effective treatment
Drug resistance
Side effects

Enterobacteriaceae causing community-acquired urinary tract infections showed resistance to commonly used antibiotics, highlighting the need for alternative treatment options like fosfomycin and nitrofurantoin.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.